MedTrace Logo

Study of the Gut Hormone Analogue Y14 in Adult Subjects

NCT03673111 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 77

Last updated 2025-03-18

Study results available
· View outcomes & findings →

Summary

A randomised, placebo controlled Phase I study to investigate investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of Y14 in adult subjects.

Conditions

Interventions

DRUG

Y14

Gut hormone analogue

DRUG

Placebo

0.9% saline

Sponsors & Collaborators

Principal Investigators

  • Stephen Bloom, FMedSci, FRS · Sponsor Chief Investigator, Imperial College London

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2017-04-10
Primary Completion
2019-02-13
Completion
2019-02-13

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03673111 on ClinicalTrials.gov